Diagnostic fluorescence in situ hybridisation (FISH) testing for Anaplastic Lymphoma Kinase (ALK) in advanced non-small cell lung cancer (NSCLC) to determine eligibility for crizotinib treatment (co-dependent). (Resubmission)

Status Complete
Type Re-application
Pre-PASC consultation -
Pre-MSAC consultation -
Outcome Supported

Application details

Reason for application

Service or technology in this application

ALK FISH testing identifies tumours that carry the ALK rearrangement obtained from patients with advanced NSCLC. Subsidy from the Pharmaceutical Benefits Scheme is also being sought for crizotinib for the treatment of patients with the ALK rearrangement.

Medical condition this application addresses

ALK-positive advanced NSCLC.

Previous applications

1250 – Testing of the ALK gene in tumour material from patients with non-small cell lung cancer to determine eligibility for treatment with crizotinib

Application documents

PICO confirmation

Download PDF - 585.89 KB

Download Word - 5.98 MB

Public summary document

Download PDF - 273.97 KB

Download Word - 111.27 KB

We aim to provide documents in an accessible format. If you're having problems using a document with your accessibility tools, please contact us for help.

Meetings to consider this application

PASC meeting: -
ESC meeting: 12 to 13 June 2014
MSAC meeting:
- 3 October 2014
- 26 to 28 November 2014

Sub menu

1250.1 – Diagnostic fluorescence in situ hybridisation (FISH) testing for Anaplastic Lymphoma Kinase (ALK) in advanced non-small cell lung cancer (NSCLC) to determine eligibility for crizotinib treatment (co-dependent). (Resubmission)